Core Viewpoint - TATA Health (01255) has received a letter from the Stock Exchange regarding additional guidelines for the resumption of trading, which includes conducting an independent internal control review to demonstrate sufficient internal controls and procedures in compliance with listing rules [1] Summary by Relevant Sections - Company Announcement - TATA Health announced on September 12, 2025, that it received a letter from the Stock Exchange detailing additional guidelines for the resumption of trading [1] - Compliance Requirements - The company is required to conduct an independent internal control review and prove that it has established adequate internal controls and procedures to meet its responsibilities under the listing rules [1]
TATA健康(01255)接获联交所额外复牌指引